<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:Tahoma;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
        {font-family:Verdana;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:purple;
        text-decoration:underline;}
span.EmailStyle17
        {mso-style-type:personal;
        font-family:"Verdana","sans-serif";
        color:windowtext;}
span.EmailStyle18
        {mso-style-type:personal-reply;
        font-family:"Calibri","sans-serif";
        color:#1F497D;}
.MsoChpDefault
        {mso-style-type:export-only;
        font-size:10.0pt;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
        {page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See below for a half dozen topics with links to articles.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>As always, use the delete key for those not of interest you.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>] <br><b>Sent:</b> March 30, 2019 10:52 AM<br><b>To:</b> PC Support Group<br><b>Subject:</b> What's New in PCa (March)<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>Active Surveillance. </span></b><span lang=EN-US style='font-size:12.0pt'>Over the last few years, as Active Surveillance has gained a higher profile<b>, </b>many of us including myself, in the Gleason 3+4 cohort (now called Gleason Grade Group 2) have wondered if we would have been candidates for AS and been able to avoid the side effects that inevitable accompany surgery or radiation.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'>This latest report </span><span lang=EN-US><a href="https://www.auajournals.org/doi/10.1016/j.juro.2018.09.042">https://www.auajournals.org/doi/10.1016/j.juro.2018.09.042</a> concludes that </span><span lang=EN-US style='font-family:"Arial","sans-serif";color:#333333;background:#F6F5F5'>caution should be exercised in offering active surveillance to men with prostate specific antigen greater than 15 ng/ml or Grade Group 2 prostate cancer. </span><span lang=EN-US style='font-size:12.0pt'>This agrees with what I have read from Dr. Klotz at Sunnybrook, so no reason for decision regret on that score.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>PSA After Surgery. </span></b><span lang=EN-US style='font-size:12.0pt'>We all hope to hear that we have undetectable PSA when that first test comes around 6 weeks after our surgery. This European Urology report confirms that a detectable PSA result usually is a sign that the cancer is not gone <a href="https://www.europeanurology.com/article/S0302-2838(19)30094-6/fulltext">https://www.europeanurology.com/article/S0302-2838(19)30094-6/fulltext</a></span><span lang=EN-US> </span><span lang=EN-US style='font-size:12.0pt'>and will likely need follow-up radiation</span><span lang=EN-US>.</span><span lang=EN-US style='font-size:12.0pt'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>Reading this with your Morning Coffee?  </span></b><span lang=EN-US style='font-size:12.0pt'>(dare I say that coffee is the flavour of the month?)<b><o:p></o:p></b></span></p><p class=MsoNormal><i><span lang=EN-US style='font-size:12.0pt'>Scientists identify compounds in coffee which may inhibit prostate cancer</span></i><span lang=EN-US> <br></span><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a href="https://www.sciencedaily.com/releases/2019/03/190318111955.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fprostate_cancer+%28Prostate+Cancer+News+--+ScienceDaily%29" target="_blank">https://www.sciencedaily.com/releases/2019/03/190318111955.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fprostate_cancer+%28Prostate+Cancer+News+--+ScienceDaily%29</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'><o:p> </o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Coffee Chemical Could Curb Prostate Cancer</span></i><span lang=EN-US><br><u><span style='color:blue'><a href="https://www.medicalnewstoday.com/articles/324730.php?utm_source=newsletter&utm_medium=email&utm_country=CA&utm_hcp=no&utm_campaign=MNT%20Weekly%20%28non-HCP%20non-US%29%20-%20OLD%20STYLE%202019-03-20&utm_term=MNT%20Weekly%20News%20%28non-HCP%20non-US%29">https://www.medicalnewstoday.com/articles/324730.php?utm_source=newsletter&utm_medium=email&utm_country=CA&utm_hcp=no&utm_campaign=MNT%20Weekly%20%28non-HCP%20non-US%29%20-%20OLD%20STYLE%202019-03-20&utm_term=MNT%20Weekly%20News%20%28non-HCP%20non-US%29</a></span></u><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'>and an earlier report on the same:</span><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'> </span><i><span lang=EN-US style='font-size:12.0pt;color:black;background:white'>Increased consumption of Italian-style coffee appeared to have a protective effect against prostate cancer in a large observational study.” </span></i><i><span lang=EN-US style='border:none windowtext 1.0pt;padding:0cm'><o:p></o:p></span></i></p><p class=MsoNormal><i><span lang=EN-US style='font-size:12.0pt;color:#1F497D'><a href="http://www.cancernetwork.com/news/coffee-had-protective-effect-prostate-cancer-risk?GUID=933F4D61-8C8A-458A-85C3-D80E97B5FAF2&XGUID=&rememberme=1&ts=05052017">http://www.cancernetwork.com/news/coffee-had-protective-effect-prostate-cancer-risk?GUID=933F4D61-8C8A-458A-85C3-D80E97B5FAF2&XGUID=&rememberme=1&ts=05052017</a><o:p></o:p></span></i></p><p class=MsoNormal><i><span lang=EN-US style='font-size:12.0pt;color:#1F497D'><o:p> </o:p></span></i></p><p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>What to Expect from Lupron Treatment. </span></b><span lang=EN-US style='font-size:12.0pt'>Not really anything new but a good introduction to ADT (hormone therapy) for anyone about to start on this for their PCa.<br><a href="https://www.medicalnewstoday.com/articles/324480.php">https://www.medicalnewstoday.com/articles/324480.php</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=EN-US style='font-size:12.0pt'>More on ADT</span></b><span lang=EN-US style='font-size:12.0pt'>. If you want or need even more detail on ADT – what it is, how it works and how to cope with side effects, then grab another coffee and listen to this podcast<br></span><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a href="https://www.buzzsprout.com/188080/994097-remediating-hormone-therapy-adt-side-effects-for-men-with-prostate-cancer?fbclid=IwAR12n8xFgQKjM7pGDM-AdjFxYnnXCSCHydxMZ9aydb-v0nI7VFL0tq-hC68">https://www.buzzsprout.com/188080/994097-remediating-hormone-therapy-adt-side-effects-for-men-with-prostate-cancer?fbclid=IwAR12n8xFgQKjM7pGDM-AdjFxYnnXCSCHydxMZ9aydb-v0nI7VFL0tq-hC68</a><o:p></o:p></span></p><p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>Is it Benign or Aggressive? </span></b><span lang=EN-US style='font-size:12.0pt'>Work continues to answer that age-old question about prostate cancer <a href="http://www.prostatecancer.ca/Prostate-Cancer-Canada-Blog/Mars-2019/Hidden-clue-in-blood-could-help-fight-aggressive-p?utm_source=twitter&utm_medium=social&utm_campaign=research">http://www.prostatecancer.ca/Prostate-Cancer-Canada-Blog/Mars-2019/Hidden-clue-in-blood-could-help-fight-aggressive-p?utm_source=twitter&utm_medium=social&utm_campaign=research</a></span><span lang=EN-US><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt'><o:p> </o:p></span></p></div></body></html>